Thiogenesis Therapeutics, Corp.
Financial Statements (IFRS) · Amounts in CAD
Income Statement
Balance Sheet
Cash Flow
| Line Item | FY 2024Dec 31, 2024 | FY 2023Dec 31, 2023 | FY 2022Dec 31, 2022 | FY 2022Feb 28, 2022 | FY 2021Dec 31, 2021 |
|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Selling General And Administration | 1.4M | 1.0M | 933,087 | 218,210 | -- |
| General And Administrative Expense | 1.4M | 1.0M | 933,087 | 218,210 | -- |
| Research And Development | 2.2M | 4.2M | 1.1M | -- | 1.4M |
| Other Operating Expenses | -- | -- | -34,132 | 6,468 | -393,429 |
| Operating Expense | 3.6M | 5.2M | 2.0M | 224,678 | -- |
| Operating Income | -3.6M | -5.2M | -2.0M | -224,678 | -- |
| EBIT | -3.6M | -5.2M | -3.9M | -224,431 | -- |
| Interest Expense | -- | 0.00 | 4,123 | 26.00 | 3,003 |
| Interest Expense Non Operating | -- | 0.00 | 4,123 | 26.00 | 3,003 |
| Interest Income | 200,327 | 171,165 | 6,181 | 247.00 | -- |
| Interest Income Non Operating | 200,327 | 171,165 | 6,181 | 247.00 | -- |
| Net Interest Income | 200,327 | 171,165 | 2,058 | 221.00 | -- |
| Other Income Expense | 233,217 | -28,155 | -2.0M | -- | 63,807 |
| Other Non Operating Income Expenses | -- | -- | -2.0M | -- | -- |
| Special Income Charges | -- | 0.00 | -2.0M | -- | 0.00 |
| Restructuring And Mergern Acquisition | -- | -- | 2.0M | -- | 0.00 |
| Gain On Sale Of Security | 233,217 | -28,155 | 61,465 | -- | 63,807 |
| Pretax Income | -3.1M | -5.1M | -3.9M | -224,457 | -- |
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Net Income From Continuing And Discontinued Operation | -3.1M | -5.1M | -3.9M | -224,457 | -- |
| Net Income From Continuing Operation Net Minority Interest | -3.1M | -5.1M | -3.9M | -224,457 | -- |
| Net Income Including Noncontrolling Interests | -3.1M | -5.1M | -3.9M | -224,457 | -- |
| Net Income Common Stockholders | -3.1M | -5.1M | -3.9M | -224,457 | -- |
| Net Income | -3.1M | -5.1M | -3.9M | -224,457 | -- |
| EBITDA | -3.6M | -5.2M | -3.9M | -224,431 | -- |
| Normalized EBITDA | -3.8M | -5.2M | -2.0M | -224,431 | -- |
| Basic EPS | -0.07 | -0.13 | -0.16 | -0.01 | -- |
| Diluted EPS | -0.07 | -0.13 | -0.16 | -0.01 | -- |
| Basic Average Shares | 45.4M | 39.1M | 25.3M | 27.9M | -- |
| Diluted Average Shares | 45.4M | 39.1M | 25.3M | 27.9M | -- |
| Total Unusual Items | 233,217 | -28,155 | -2.0M | -- | 63,807 |
| Total Unusual Items Excluding Goodwill | 233,217 | -28,155 | -2.0M | -- | 63,807 |
| Tax Rate For Calcs | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Normalized Income | -3.4M | -5.0M | -2.0M | -224,457 | -- |
| Diluted NI Availto Com Stockholders | -3.1M | -5.1M | -3.9M | -224,457 | -- |
| Net Income Continuous Operations | -3.1M | -5.1M | -3.9M | -224,457 | -- |
| Net Non Operating Interest Income Expense | 200,327 | 171,165 | 2,058 | 221.00 | -- |
| Other Gand A | 980,582 | 665,750 | 538,622 | 218,210 | -- |
| Other Special Charges | -- | -- | 2.0M | -- | -- |
| Salaries And Wages | 375,357 | 377,314 | 394,465 | -- | 0.00 |
| Total Expenses | 3.6M | 5.2M | 2.0M | 224,678 | -- |
| Line Item | FY 2024Dec 31, 2024 | FY 2023Dec 31, 2023 | FY 2022Dec 31, 2022 | FY 2022Feb 28, 2022 | FY 2021Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash And Cash Equivalents | 3.8M | 7.1M | 6.2M | -- | 62,549 |
| Cash Cash Equivalents And Short Term Investments | 3.8M | 7.1M | 6.2M | -- | 62,549 |
| Accounts Receivable | 2,613 | 6,003 | 7,318 | -- | 13,215 |
| Receivables | 87,928 | 85,315 | 55,987 | 247.00 | -- |
| Prepaid Assets | 47,596 | 81,377 | 38,624 | 25,000 | -- |
| Current Assets | 4.0M | 7.2M | 6.3M | 3.4M | -- |
| Total Non Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Total Assets | 4.0M | 7.2M | 6.3M | 3.4M | -- |
| Current Debt | -- | -- | -- | -- | 461,855 |
| Current Debt And Capital Lease Obligation | -- | -- | -- | -- | 461,855 |
| Payables | -- | -- | -- | 3.2M | -- |
| Payables And Accrued Expenses | 557,876 | 1.7M | 307,151 | 3.5M | -- |
| Current Accrued Expenses | -- | -- | -- | 245,708 | -- |
| Other Current Liabilities | -- | -- | -- | -- | 150,413 |
| Current Liabilities | 557,876 | 1.7M | 307,151 | 3.5M | -- |
| Total Non Current Liabilities Net Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Total Liabilities Net Minority Interest | 557,876 | 1.7M | 307,151 | 3.5M | -- |
| Common Stock | 16.1M | 15.0M | 11.1M | 302,473 | -- |
| Capital Stock | 16.1M | 15.0M | 11.1M | 302,473 | -- |
| Additional Paid In Capital | -- | -- | -- | 89,884 | -- |
| Retained Earnings | -14.3M | -11.1M | -6.2M | -453,423 | -- |
| Gains Losses Not Affecting Retained Earnings | 1.6M | 1.7M | 1.0M | -- | 28,646 |
| Other Equity Adjustments | 1.6M | 1.7M | 1.0M | -- | 28,646 |
| Common Stock Equity | 3.4M | 5.5M | 6.0M | -61,066 | -- |
| Stockholders Equity | 3.4M | 5.5M | 6.0M | -61,066 | -- |
| Total Equity Gross Minority Interest | 3.4M | 5.5M | 6.0M | -61,066 | -- |
| Total Capitalization | 3.4M | 5.5M | 6.0M | -61,066 | -- |
| Net Tangible Assets | 3.4M | 5.5M | 6.0M | -61,066 | -- |
| Tangible Book Value | 3.4M | 5.5M | 6.0M | -61,066 | -- |
| Working Capital | 3.4M | 5.5M | 6.0M | -61,066 | -- |
| Invested Capital | 3.4M | 5.5M | 6.0M | -61,066 | -- |
| Total Debt | -- | -- | -- | -- | 461,855 |
| Net Debt | -- | -- | -- | -- | 399,306 |
| Share Issued | 46.0M | 44.6M | 38.9M | 27.9M | -- |
| Ordinary Shares Number | 46.0M | 44.6M | 38.9M | 27.9M | -- |
| Accrued Interest Receivable | -- | -- | -- | 247.00 | -- |
| Current Notes Payable | -- | -- | 0.00 | -- | 193,400 |
| Dueto Related Parties Current | -- | -- | -- | 3.2M | -- |
| Other Current Borrowings | -- | -- | -- | -- | 268,455 |
| Other Receivables | -- | -- | 34,742 | -- | 155,213 |
| Restricted Cash | -- | -- | -- | 3.4M | -- |
| Taxes Receivable | 85,315 | 79,312 | 13,927 | -- | -- |
| Line Item | FY 2024Dec 31, 2024 | FY 2023Dec 31, 2023 | FY 2022Dec 31, 2022 | FY 2022Feb 28, 2022 | FY 2021Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | -3.9M | -3.2M | -2.1M | -67,076 | -- |
| Cash Flow From Continuing Operating Activities | -3.9M | -3.2M | -2.1M | -67,076 | -- |
| Stock Based Compensation | 348,982 | 480,914 | 524,366 | -- | 7,199 |
| Change In Working Capital | -1.1M | 1.3M | -568,807 | 157,381 | -- |
| Changes In Account Receivables | -2,613 | -64,070 | -7,991 | -- | -11,872 |
| Change In Receivables | -2,613 | -29,328 | 112,480 | -25,247 | -- |
| Change In Payables And Accrued Expense | -1.2M | 1.4M | -642,663 | 182,628 | -- |
| Change In Payable | -- | 1.4M | -642,663 | -- | -- |
| Other Non Cash Items | -- | -- | 1.9M | -- | -- |
| Sale Of Business | -- | 0.00 | 107,457 | -- | 0.00 |
| Investing Cash Flow | -- | 0.00 | 107,457 | -- | 0.00 |
| Cash Flow From Continuing Investing Activities | -- | 0.00 | 107,457 | -- | 0.00 |
| Issuance Of Debt | -- | -- | -- | -- | 143,702 |
| Repayment Of Debt | -- | 0.00 | -175,172 | -- | 0.00 |
| Net Issuance Payments Of Debt | -- | 0.00 | -175,172 | -- | 143,702 |
| Issuance Of Capital Stock | 0.00 | 4.1M | 4.9M | -- | 674,813 |
| Net Common Stock Issuance | 0.00 | 4.1M | 4.9M | -- | 674,813 |
| Financing Cash Flow | 723,400 | 4.1M | 8.1M | 3.3M | -- |
| Cash Flow From Continuing Financing Activities | 723,400 | 4.1M | 8.1M | 3.3M | -- |
| Effect Of Exchange Rate Changes | -31,274 | 7,584 | -10,983 | -- | -7,024 |
| Changes In Cash | -3.2M | 872,763 | 6.1M | 3.3M | -- |
| Beginning Cash Position | 7.1M | 6.2M | 62,549 | 146,431 | -- |
| End Cash Position | 3.8M | 7.1M | 6.2M | 3.4M | -- |
| Free Cash Flow | -3.9M | -3.2M | -2.1M | -67,076 | -- |
| Change In Account Payable | -- | 1.4M | -642,663 | -- | -- |
| Change In Accrued Expense | -- | -- | -- | 182,628 | -- |
| Change In Prepaid Assets | 33,781 | -42,753 | -38,624 | -- | 31,830 |
| Common Stock Issuance | 0.00 | 4.1M | 4.9M | -- | 674,813 |
| Gain Loss On Investment Securities | -- | -- | -61,465 | -- | -63,807 |
| Net Business Purchase And Sale | -- | 0.00 | 107,457 | -- | 0.00 |
| Net Income From Continuing Operations | -3.1M | -5.1M | -3.9M | -224,457 | -- |
| Net Other Financing Charges | -- | -- | -- | -194,542 | -- |
| Net Short Term Debt Issuance | -- | 0.00 | -175,172 | -- | 143,702 |
| Operating Gains Losses | -- | -- | -56,191 | -- | -63,807 |
| Proceeds From Stock Option Exercised | 723,400 | 0.00 | 3.4M | 3.5M | -- |
| Short Term Debt Issuance | -- | -- | -- | -- | 143,702 |
| Short Term Debt Payments | -- | 0.00 | -175,172 | -- | 0.00 |